Physician profile
Daniel S Manavi
NPI 1467477885
$5,811.55
in general payments reported to CMS, 2019-2025
22 companies · $765 in 2025
The $765 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,301 · 2020: $570 · 2021: $965 · 2022: $999 · 2023: $768 · 2024: $443 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,976.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,621.32 | 2019-2024 | Jot Dx, Aveir, Merlin@Home |
| Amgen INC. | $1,038.39 | 2019-2025 | Repatha, Avsola, Repatha |
| E.R. Squibb & Sons, L.L.C. | $523.69 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $399.82 | 2021-2025 | Wegovy |
| Boston Scientific Corporation | $305.15 | 2019-2023 | Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.98 | 2023-2025 | Jardiance |
| Pfizer INC. | $273.98 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $214.80 | 2019-2023 | Xarelto |
| Mannkind Corporation | $164.36 | 2021 | |
| Atricure, INC. | $155.26 | 2025 | Atriclip Laa Exclusion System, Synergy Ablation System |
| Astrazeneca Pharmaceuticals LP | $147.04 | 2020-2024 | Farxiga |
| Lilly USA, LLC | $130.69 | 2022 | |
| Intuitive Surgical, INC. | $115.46 | 2022 | |
| Glaxosmithkline, LLC. | $91.37 | 2020 | |
| Abbvie INC. | $87.93 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $85.79 | 2022-2025 | |
| Impulse Dynamics (USA) INC. | $52.18 | 2023 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $50.38 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $41.78 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $16.33 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $4.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Manavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.